In May, the Trump Administration announced its Blueprint to Lower Drug Prices and HHS Secretary Azar issued a Request for Information seeking comments from interested parties “to help shape future policy development and agency action” related to drug pricing issues. Since that time, many industry commentators questioned whether any of the vague goals in the Blueprint would or could be turned into concrete action.
This month, the Trump Administration has attempted to answer that question through a variety of HHS and FDA initiatives. Here’s what you need to know about drug pricing developments so far in July. Continue Reading Significant Drug Pricing Developments in July – Here’s What You Need To Know